Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | SHBG | P04278 | 2/20 | 0.58 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.51 |
| ▸ | MGAM | O43451 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22100505 | 1.00 | AR (0.61) | ARESR1ESR2CYP19A1LMNA | |
| SCHEMBL10404807 | 0.85 | AR (0.60) | ARESR1ESR2CYP19A1LMNA | |
| SCHEMBL10403372 | 0.85 | AR (0.60) | ARESR1ESR2CYP19A1LMNA | |
| SCHEMBL10403371 | 0.85 | AR (0.60) | ARESR1ESR2CYP19A1LMNA | |
| SCHEMBL15874948 | 0.81 | AR (0.64) | ARESR1ESR2CYP19A1LMNA | |
| SCHEMBL16225971 | 0.81 | NR1I3 (0.59) | ARESR1ESR2CYP19A1LMNA | |
| SCHEMBL16225750 | 0.81 | NR1I3 (0.59) | ARESR1ESR2CYP19A1LMNA | |
| SCHEMBL12478628 | 0.79 | CYP17A1 (0.50) | ARESR1ESR2LMNAGPBAR1 | |
| SCHEMBL5694830 | 0.77 | CYP19A1 (0.67) | CYP19A1LMNAGPBAR1CYP3A4CYP2C19 | |
| SCHEMBL22069477 | 0.77 | CYP19A1 (0.67) | CYP19A1LMNAGPBAR1CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220054501-A1 | MEDICATION AGAINST ESTROGEN-RECEPTOR b (ER.beta) POSITIVE BREAST TUMOR | DCIC BIOPHARMACEUTICAL LIMITED (HK) | 2022-02-24 | — | — | US | claimed |
| EP-3860611-A1 | MEDICATION AGAINST ESTROGEN-RECEPTOR SS (ERSS) POSITIVE BREAST TUMOR | dcic Biopharmaceutical Limited (HK) | 2021-08-11 | — | — | EP | claimed |
| WO-2020120739-A1 | MEDICATION AGAINST ESTROGEN-RECEPTOR ß (ERß) POSITIVE BREAST TUMOR | DCIC BIOPHARMACEUTICAL LIMITED (CN) | 2020-06-18 | — | — | WO | claimed |
| EP-3666276-A1 | MEDICATION AGAINST ESTROGEN-RECEPTOR BETA (ERBETA) POSITIVE BREAST TUMOR | dcic Biopharmaceutical Limited (HK) | 2020-06-17 | — | — | EP | claimed |
| US-20220054501-A1 | MEDICATION AGAINST ESTROGEN-RECEPTOR b (ER.beta) POSITIVE BREAST TUMOR | DCIC BIOPHARMACEUTICAL LIMITED (HK) | 2022-02-24 | — | — | US | disclosed |
| EP-3860611-A1 | MEDICATION AGAINST ESTROGEN-RECEPTOR SS (ERSS) POSITIVE BREAST TUMOR | dcic Biopharmaceutical Limited (HK) | 2021-08-11 | — | — | EP | disclosed |
| WO-2020120739-A1 | MEDICATION AGAINST ESTROGEN-RECEPTOR ß (ERß) POSITIVE BREAST TUMOR | DCIC BIOPHARMACEUTICAL LIMITED (CN) | 2020-06-18 | — | — | WO | disclosed |
| EP-3666276-A1 | MEDICATION AGAINST ESTROGEN-RECEPTOR BETA (ERBETA) POSITIVE BREAST TUMOR | dcic Biopharmaceutical Limited (HK) | 2020-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054501-A1 | MEDICATION AGAINST ESTROGEN-RECEPTOR b (ER.beta) POSITIVE BREAST TUMOR | ESR1, GPER1, CYP19A1 | AR 66/4885ESR1 1/4885ESR2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.